FDA funded under six-month continuing resolution
This article was originally published in The Gray Sheet
Executive Summary
Continuing resolution approved in the House Sept. 24 to fund the government at 2008 appropriations levels through March 6, 2009, includes an additional $150 million for FDA - the same amount that the agency received in supplemental appropriations in June ("1The Gray Sheet" June 23, 2008, p. 6). The additional amount, which will be released in increments over the covered six-month period, represents "critical resources necessary to ensure the safety of food, prescription drugs and medical devices," says Rep. Rosa DeLauro, D-Conn., chair of the Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Subcommittee. The Senate was scheduled to vote on the continuing resolution Sept. 27
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.